Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Dr Martens CEO to step down amid bleak profit outlook

(Sharecast News) - UK bootmaker Dr Martens said chief executive Kenny Wilson has decided to step down as the company issued another profit warning for the current financial year amid continuing woes in the US, its biggest market. Wilson will be replaced by brand officer Ije Nwokorie before the end of the current financial year, Dr Martens said in a statement.

"There is a wide range of potential outcomes for full-year 2025 given that we have only recently started the year. However, we have assumed that revenue declines by single-digit percentage year-on-year and ... we could see a worst-case scenario of profit-before-tax of around one-third of the 2024 level," it added.

The company issued four profits warnings last year as a tough consumer environment in the US continues to affect sales of its famous boots.

On Tuesday it said USA wholesale revenue was expected to be down by double digits year-on-year, with its autumn/winter order book - which makes up the majority of the second half of US wholesales - forecast to be "significantly" down and hitting profits by £20m.

There would also be a further one-off £35m hit from single-digit cost base inflation and retaining staff.

"As previously communicated, we do not anticipate increasing prices further this year, and therefore in full-year 2025 we are unable to offset cost inflation as we have in prior years," the company said.

"Given the ongoing challenging performance of our US wholesale business, we expect to continue to require the additional inventory storage facilities in this market through 2025, and therefore the majority of the £15m of additional costs incurred in 2024 are expected to repeat."

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

Goldman Sachs downgrades SSP to 'sell', prefers WH Smith
(Sharecast News) - Goldman Sachs downgraded SSP on Monday to 'sell' from 'neutral' "on a relative basis" as it took a look at European travel concessions.
UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.